End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
42.4 CNY | -1.12% | +0.02% | -13.36% |
05-28 | Warrant Pharmaceutical's Unit Gets Nod to Market Benidipine Hydrochloride | MT |
04-19 | Hunan Warrant Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 4,591 | 3,977 | - | - |
Enterprise Value (EV) 1 | 4,591 | 3,977 | 3,977 | 3,977 |
P/E ratio | 21.8 x | - | - | - |
Yield | - | - | - | - |
Capitalization / Revenue | - | 2.27 x | 1.92 x | 1.64 x |
EV / Revenue | - | 2.27 x | 1.92 x | 1.64 x |
EV / EBITDA | - | 10.9 x | 9.06 x | 7.75 x |
EV / FCF | - | - | - | - |
FCF Yield | - | - | - | - |
Price to Book | - | 2.09 x | 1.88 x | 1.68 x |
Nbr of stocks (in thousands) | 93,800 | 93,800 | - | - |
Reference price 2 | 48.94 | 42.40 | 42.40 | 42.40 |
Announcement Date | 25/02/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | 1,753 | 2,076 | 2,426 |
EBITDA 1 | - | 364 | 439 | 513 |
EBIT 1 | - | 316 | 382 | 450 |
Operating Margin | - | 18.02% | 18.4% | 18.55% |
Earnings before Tax (EBT) | - | - | - | - |
Net income | 211.4 | - | - | - |
Net margin | - | - | - | - |
EPS | 2.250 | - | - | - |
Free Cash Flow | - | - | - | - |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 25/02/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2024 Q1 |
---|---|
Net sales 1 | 372.9 |
EBITDA | - |
EBIT | - |
Operating Margin | - |
Earnings before Tax (EBT) | - |
Net income | - |
Net margin | - |
EPS | - |
Dividend per Share | - |
Announcement Date | 19/04/24 |
Balance Sheet Analysis
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | - | - |
ROE (net income / shareholders' equity) | - | 13.9% | 15.2% | 16% |
ROA (Net income/ Total Assets) | - | 11% | 12.1% | 12.8% |
Assets | - | - | - | - |
Book Value Per Share 1 | - | 20.30 | 22.60 | 25.30 |
Cash Flow per Share | - | - | - | - |
Capex 2 | - | 96 | 80 | 64 |
Capex / Sales | - | 5.48% | 3.85% | 2.64% |
Announcement Date | 25/02/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.36% | 549M | |
+48.53% | 780B | |
+41.24% | 627B | |
-6.37% | 353B | |
+20.93% | 334B | |
+8.21% | 296B | |
+17.53% | 244B | |
-1.15% | 217B | |
+11.26% | 214B | |
+4.40% | 161B |
- Stock Market
- Equities
- 688799 Stock
- Financials Hunan Warrant Pharmaceutical Co.,Ltd